{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:06:43Z","timestamp":1790100403100,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","award":["31570163"],"award-info":[{"award-number":["31570163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Project for Innovative Pharmaceuticals","award":["2015ZX09J15105-002"],"award-info":[{"award-number":["2015ZX09J15105-002"]}]},{"name":"Science and Technology Projects of Guangzhou","award":["201504010032"],"award-info":[{"award-number":["201504010032"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong","doi-asserted-by":"publisher","award":["2015A030313803"],"award-info":[{"award-number":["2015A030313803"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.antiviral.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T13:12:13Z","timestamp":1522847533000},"page":"17-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55"],"prefix":"10.1016","volume":"154","author":[{"given":"Xingui","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baimao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.04.001_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib2","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3201\/1708.101760","article-title":"Deaths associated with human adenovirus-14p1 infections, Europe, 2009-2010","volume":"17","author":"Carr","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.001_bib3","article-title":"Adenoviruses associated with acute respiratory diseases reported in Beijing from 2011 to 2013","volume":"10","author":"Chen","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.04.001_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jmii.2015.08.006","article-title":"Risk factor analysis and molecular epidemiology of respiratory adenovirus infections among children in northern Taiwan, 2009-2013","volume":"50","author":"Cheng","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.antiviral.2018.04.001_bib5","first-page":"615","article-title":"Identification and typing of adenovirus from acute respiratory infections in pediatric patients in Beijing from 2003 to 2012","volume":"29","author":"Deng","year":"2013","journal-title":"Chin. J. virology"},{"key":"10.1016\/j.antiviral.2018.04.001_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcv.2012.04.018","article-title":"Severe community-acquired pneumonia caused by adenovirus type 11 in immunocompetent adults in Beijing","volume":"54","author":"Gu","year":"2012","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib7","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s10096-011-1406-8","article-title":"Detection of three human adenovirus species in adults with acute respiratory infection in China","volume":"31","author":"Guo","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/oxfordjournals.aje.a121632","article-title":"Occurrence of respiratory illness due to an atypical strain of adenovirus type 11 during a large outbreak in Spanish military recruits","volume":"99","author":"Hierholzer","year":"1974","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2105\/AJPH.48.2.153","article-title":"Efficacy of and indications for use of adenovirus vaccine","volume":"48","author":"Hilleman","year":"1958","journal-title":"Am. J. Publ. Health Nation's Health"},{"key":"10.1016\/j.antiviral.2018.04.001_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.vaccine.2012.12.029","article-title":"History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system","volume":"31","author":"Hoke","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.001_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1086\/653083","article-title":"Molecular epidemiology and brief history of emerging adenovirus 14-associated respiratory disease in the United States","volume":"202","author":"Kajon","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.001_bib12","doi-asserted-by":"crossref","first-page":"e53614","DOI":"10.1371\/journal.pone.0053614","article-title":"Adenovirus serotype 3 and 7 infection with acute respiratory failure in children in Taiwan, 2010-2011","volume":"8","author":"Lai","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.04.001_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000150218","article-title":"Genetic relationship between thirteen genome types of adenovirus 11, 34, and 35 with different tropisms","volume":"32","author":"Li","year":"1991","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2018.04.001_bib15","first-page":"110","article-title":"Clinical and molecular features of adenovirus type 2, 3, and 7 infections in children in an outbreak in Taiwan, 2011","volume":"23","author":"Lin","year":"2017","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.001_bib16","article-title":"Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector","volume":"9","author":"Liu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.04.001_bib17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/irv.12232","article-title":"Epidemiology of human adenovirus and molecular characterization of human adenovirus 55 in China, 2009-2012","volume":"8","author":"Lu","year":"2014","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2018.04.001_bib18","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1016\/j.vaccine.2015.10.117","article-title":"Neutralizing epitopes mapping of human adenovirus type 14 hexon","volume":"33","author":"Ma","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.001_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ygeno.2013.09.001","article-title":"Genomic analysis of HAdV-B14 isolate from the outbreak of febrile respiratory infection in China","volume":"102","author":"Mi","year":"2013","journal-title":"Genomics"},{"key":"10.1016\/j.antiviral.2018.04.001_bib20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1139\/m57-095","article-title":"The use of beta-propiolactone for the preparation of virus vaccines. I. Selection of reaction conditions","volume":"3","author":"Polley","year":"1957","journal-title":"Can. J. Microbiol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib21","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1128\/JVI.07076-11","article-title":"Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions","volume":"86","author":"Qiu","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib22","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/cid\/ciu507","article-title":"Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines","volume":"59","author":"Radin","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2018.04.001_bib23","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/srep01812","article-title":"Molecular evolution of human adenoviruses","volume":"3","author":"Robinson","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.04.001_bib24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11908-014-0416-y","article-title":"Adenovirus: current epidemiology and emerging approaches to prevention and treatment","volume":"16","author":"Sandkovsky","year":"2014","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.antiviral.2018.04.001_bib25","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/JVI.00354-11","article-title":"Using the whole-genome sequence to characterize and name human adenoviruses","volume":"85","author":"Seto","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jcv.2013.09.025","article-title":"Characterizing, typing, and naming human adenovirus type 55 in the era of whole genome data","volume":"58","author":"Seto","year":"2013","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib27","article-title":"Human adenovirus serotype 3 vector packaged by a rare serotype 14 hexon","volume":"11","author":"Su","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.04.001_bib28","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib29","article-title":"Severe community-acquired pneumonia caused by human adenovirus in immunocompetent adults: a multicenter case series","volume":"11","author":"Tan","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.04.001_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.virusres.2011.06.017","article-title":"Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon","volume":"160","author":"Tian","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.04.001_bib31","first-page":"393","article-title":"Cloning and expression of hexon protein of human respiratory adenovirus of three serotypes and analysis of antigenicity of the recombinant proteins","volume":"34","author":"Tian","year":"2014","journal-title":"Chin. J. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib32","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.3390\/v7102896","article-title":"Identification and application of neutralizing epitopes of human adenovirus type 55 hexon protein","volume":"7","author":"Tian","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.04.001_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virusres.2015.06.002","article-title":"Mapping the epitope of neutralizing monoclonal antibodies against human adenovirus type 3","volume":"208","author":"Tian","year":"2015","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.04.001_bib34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/JCM.01694-09","article-title":"Computational analysis identifies human adenovirus type 55 as a re-emergent acute respiratory disease pathogen","volume":"48","author":"Walsh","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.04.001_bib41","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1128\/JVI.00205-12","article-title":"A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses","volume":"86","author":"Wang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib35","doi-asserted-by":"crossref","first-page":"23014","DOI":"10.1038\/srep23014","article-title":"Phylogenetic evidence for intratypic recombinant events in a novel human adenovirus C that causes severe acute respiratory infection in children","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.04.001_bib36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/jmv.24749","article-title":"First isolation of a new type of human adenovirus (genotype 79), species Human mastadenovirus B (B2) from sewage water in Japan","volume":"89","author":"Yoshitomi","year":"2017","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.04.001_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.virol.2012.12.014","article-title":"Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera","volume":"437","author":"Yu","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.04.001_bib38","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1016\/j.vaccine.2009.06.041","article-title":"Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein","volume":"27","author":"Yuan","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.001_bib39","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.vaccine.2008.12.039","article-title":"Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector","volume":"27","author":"Zhang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.001_bib40","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/emi.2017.29","article-title":"Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China","volume":"6","author":"Zheng","year":"2017","journal-title":"Emerg. Microbes Infect."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217308136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217308136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:03Z","timestamp":1759062423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217308136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":42,"alternative-id":["S0166354217308136"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}